DrugPatentWatch Database Preview
Drugs in Development Information for Oprelvekin
Development status for investigational drug Oprelvekin: Patents, clinical trial progress, indications
Oprelvekin is an investigational drug.
There have been 4 clinical trials for Oprelvekin.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2008.
The most common disease conditions in clinical trials are Von Willebrand Diseases, Thrombocytopenia, and Leukemia, Myeloid. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, University of North Carolina, and University of Pittsburgh.
Summary for Oprelvekin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2008-01-01) |
| Vendors | 0 |
Recent Clinical Trials for Oprelvekin
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia | Pfizer | Phase 2 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | University of North Carolina | Phase 2 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
Clinical Trial Summary for Oprelvekin
Top disease conditions for Oprelvekin
Top clinical trial sponsors for Oprelvekin
US Patents for Oprelvekin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
